Table 3 DAS-28-based EULAR response in patients switchingto a second TNF antagonist, by reason for switching
Inefficacy N (%) | Adverse events N (%) | Other reasons N (%) | |
|---|---|---|---|
Good | 10 (20) | 6 (25) | 1 (10) |
Moderate | 12 (25) | 8 (30) | 2 (18) |
No response | 26 (55) | 10 (45) | 8 (72) |